The FDA on December 13, 2023, approved IWILFIN® to reduce the risk of relapse in adult and pediatric patients with high-risk Neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. IWILFIN® is a product of USWM, LLC.
Bottom Ad
Advertisement
Subscribe
